Drug Profile
GN 4474
Alternative Names: GN-4474Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Atterx Biotherapeutics
- Class Antibacterials; Bacteria; Bacterial toxins
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 30 Aug 2017 Preclinical trials in Bacterial infections in USA before August 2017 (Atterx Biotherapeutics pipeline, August 2017)
- 30 Aug 2017 Atterx Biotherapeutics announces intention to submit IND to US FDA for Bacterial infections in 2017 (Atterx Biotherapeutics pipeline, August 2017)